Robert Torray's Torray Fund: March 2026 Investment Activity Analysis

Detailed analysis of Robert Torray's Torray Fund holdings changes during the March 2026 quarter, highlighting key purchases, sales, and sector trends.

By AI Generated.May 2, 2026, 10:14 PM
Robert Torray's Torray Fund: March 2026 Investment Activity Analysis

Robert Torray, managing the Torray Fund with a total portfolio value of approximately $638 million as of March 31, 2026, demonstrated active management during the quarter, with notable shifts across various sectors. The fund's top holdings show a mix of increased allocations, decreased positions, and one newly initiated stake.

Technology remained a strong focus, with Microsoft (MSFT) leading the gains. Torray increased his position in Microsoft by over 118,000 shares, representing a significant 118.78% increase in the position's value during the quarter. This substantial growth pushed Microsoft's allocation slightly higher within the portfolio. Texas Instruments (TXN) also saw a positive move, with Torray adding shares, increasing its portfolio allocation by approximately 0.35%. Broadcom (AVGO) also benefited from Torray's buying activity, showing modest share increases and a positive percentage change.

In the Energy sector, the picture was more mixed. Phillips 66 (PSX) experienced a notable reduction, with Torray decreasing his position by over 32,000 shares, leading to a substantial 32.47% reduction in its value and allocation. Conversely, Constellation Energy (CEG) saw a dramatic increase, with Torray adding nearly 73,000 shares, resulting in a staggering 375.83% increase in its value and allocation. Chevron Corporation (CVX) also received incremental buying from Torray, albeit on a smaller scale.

Healthcare and Utilities also featured in Torray's activity. Pfizer (PFE) saw a modest increase in shares, while CNA Financial (CNA) experienced a decrease. Notably, ONEOK (OKE) represents a new position initiated by Torray during this quarter, as the position did not exist in the previous period's top holdings data. This suggests a strategic addition to the portfolio.

Royalty Pharma Plc (RPRX) saw a reduction in Torray's position, with a decrease of nearly 5,000 shares. The fund's holdings reflect a dynamic approach, balancing established positions with new additions and strategically reducing others.

For a complete view of Robert Torray's investment activities and the full portfolio composition, please visit the investor profile at https://www.insiderset.com/investor/robert-torray-torray-investment. Detailed information on individual holdings like Microsoft can be found at https://www.insiderset.com/investors/stocks/MSFT.